Human epidermal growth factor receptor 2 (HER2)-positive breast cancers are very aggressive tumors that display a poor response to hormone treatment and are treated more successfully with tyrosine kinase inhibitors such as lapatinib [51]. This evidence concerns the gene ERBB2 and breast cancer.